US 8314093
2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
granted A61PA61P1/04A61P19/02
Quick answer
US patent 8314093 (2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Nov 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61P, A61P1/04, A61P19/02, A61P29/00, A61P37/00